Back to Research

Organization profile

InSphero

InSphero is a global market leader in 3D in vitro models and organ-on-chip systems, providing highly scalable and reproducible human microtissues for non-animal drug testing. The company specializes in liver safety, metabolic diseases, and oncology, helping pharmaceutical organizations replace animal models with more predictive, human-relevant data.

Schlieren, SwitzerlandFounded 2009

Overview

1. Executive Summary (Confidence: High)

InSphero AG, founded in 2009 as a spin-off of ETH Zurich, is the industry standard-bearer for "The Model of Excellence™" in 3D cell culture.[18] Headquartered in Schlieren, Switzerland, the organization provides a suite of advanced microphysiological systems that address the high failure rate of drugs in clinical trials.[19] In November 2025, InSphero significantly expanded its technological moat by acquiring DOPPL SA and its Sun Bioscience Gri3D® technology, effectively merging the scalability of spheroids with the physiological depth of organoids.[20] The company is at the vanguard of the longevity ecosystem, offering immune-competent models and specialized metabolic assays that accelerate the discovery of therapies for age-related conditions like fibrosis and Type 1 Diabetes.[18] With a global distribution network and a laboratory hub in North America, InSphero is a critical partner for the modernization of drug discovery.[19]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.